Valuation: Realcan Pharmaceutical Group Co., Ltd.

Market Cap 5.1B 756M 653M 615M 559M 1.05B 72.48B 1.07B 7.21B 2.83B 36.25B 2.84B 2.78B 121B P/E 2024
217x
P/E 2025 322x
Enterprise Value 5.96B 884M 764M 718M 653M 1.23B 84.7B 1.25B 8.43B 3.3B 42.36B 3.32B 3.25B 141B EV / Sales 2024
0.76x
EV / Sales 2025 0.77x
Free-Float
69.07%
Yield 2024
0.37%
Yield 2025 0.06%
05-19 Realcan Pharmaceutical Group Co., Ltd. Approves Cash Dividend for 2025 for A shares, Payable on 30 June 2026 CI
04-24 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-22 Realcan Pharmaceutical Group Co., Ltd. announces Annual dividend, payable on June 30, 2026 CI
04-22 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-07 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
11-06 Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on November 11, 2024, has closed with 34,638,659 shares, representing 2.31% for CNY 101.48 million. CI
29/10/25 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
13/10/25 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
25/08/25 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
03/07/25 Realcan Pharmaceutical Vice President Detained MT
02/07/25 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
03/06/25 Yanquan No. 8 Private Securities Investment Fund, a fund managed by Jiaxing Yanquan Investment Partnership LLP cancelled the acquisition of 5.05% stake in Realcan Pharmaceutical Group Co., Ltd. from Zhang Renhua for approximately CNY 160 million. CI
03/06/25 Realcan Pharmaceutical Group Shareholder Nixes Share Transfer Deal MT
1 day-3.07%
1 week+3.89%
Current month+26.18%
1 month+27.11%
3 months+14.52%
6 months+6.12%
Current year+7.76%
1 week 3.18
Extreme 3.18
3.9
1 month 2.59
Extreme 2.59
3.9
Current year 2.38
Extreme 2.38
4.11
1 year 2.38
Extreme 2.38
4.69
3 years 2.05
Extreme 2.05
4.69
5 years 2.05
Extreme 2.05
6.73
10 years 2.05
Extreme 2.05
18.26
Manager TitleAgeSince
Director of Finance/CFO 56 25/04/2021
President 61 25/05/2023
Corporate Officer/Principal 40 29/10/2019
Director TitleAgeSince
Chairman 61 20/11/2009
Director/Board Member 43 20/11/2009
Chairman 48 07/10/2019
Date Insider Type Main position Quantity % Market Cap.
12/05/23 Sell

Founder

15,000,000 1.2902%
30/03/23 Sell

Founder

13,040,000 1.1260%
30/03/23 Sell

Chairman

2,000,000 0.1727%
Change 5-day change 1-year change 3-year change Capi.($)
-3.07%+3.89%+16.44%-7.47% 781M
+1.09%-1.21%+29.15%+108.48% 100B
-0.29%-0.93%+57.06%+172.00% 54.81B
-1.69%-2.03%+2.11%+281.58% 24.13B
-0.24%-1.73%-12.65%-16.13% 8.19B
-1.70%-2.33%-32.71%-24.87% 7.66B
+0.65%-0.88%-13.59%-20.61% 6.68B
+1.76%+5.58%+12.39%+20.87% 6.42B
0.00%-1.52%-3.17%+15.56% 4.98B
-0.60%-1.78%-7.12%-9.61% 3.69B
Average -0.22%-0.91%+4.79%+51.98% 21.76B
Weighted average by Cap. +0.37%-1.35%+26.23%+123.20%

Financials

2024 2025
Net sales 7.97B 1.18B 1.02B 960M 872M 1.64B 113B 1.67B 11.26B 4.41B 56.61B 4.44B 4.34B 189B 7.3B 1.08B 934M 879M 799M 1.5B 104B 1.52B 10.31B 4.04B 51.84B 4.06B 3.97B 173B
Net income 20.62M 3.06M 2.64M 2.48M 2.26M 4.25M 293M 4.31M 29.15M 11.42M 147M 11.48M 11.23M 488M 16.07M 2.38M 2.06M 1.94M 1.76M 3.31M 228M 3.36M 22.72M 8.9M 114M 8.95M 8.75M 380M
Net Debt 1.6B 237M 204M 192M 175M 329M 22.67B 333M 2.26B 884M 11.34B 888M 869M 37.76B 860M 128M 110M 104M 94.22M 177M 12.22B 180M 1.22B 477M 6.11B 479M 469M 20.36B
Logo Realcan Pharmaceutical Group Co., Ltd.
Realcan Pharmaceutical Group Co Ltd, formerly Realcan Pharmaceutical Co Ltd, is a China-based company mainly engaged in the provision of comprehensive medical service. The Company operates five businesses. The drug and device distribution business is mainly responsible for drug and device distribution services and comprehensive medical services. The in vitro diagnostic business covers all fields such as laboratory biochemistry, immunity, and clinical examination. The digital health business provides one-stop health management solutions. The pharmaceutical logistics business provides pharmaceutical and medical device logistics services. The traditional Chinese medicine business is engaged in the research, development and production of traditional Chinese medicine pieces, granules, new traditional Chinese medicines, liquefied traditional Chinese medicine products, and health foods. The Company mainly operates in the domestic market, with Shandong as its main market.
Employees
2,407
Date Price Change Volume
17/08/26 CN¥3.470 -3.07% 189,780,500
17/08/26 CN¥3.580 +1.42% 296,818,557
14/08/26 CN¥3.530 -4.85% 254,799,542
13/08/26 CN¥3.710 +4.51% 393,381,828
12/08/26 CN¥3.550 +9.91% 244,065,297
  1. Stock Market
  2. Stocks
  3. 002589 Stock